'Proof of the strength of our cash flow and balance sheet'
Teva signs $1.5 billion credit facility
Israel-based pharmaceutical company says new facility is part of its strategy to secure liquidity for future business needs through revolving credit lines
Drug developer Teva Pharmaceutical Industries Ltd. said Monday it signed a new three-year, $1.5 billion credit facility.
The company said the new facility is part of its strategy to secure liquidity for future business needs through revolving credit lines.
"Our ability to negotiate better terms today is proof of the strength of our cash flow and balance sheet," said Chief Financial Officer Eyal Desheh said.
The syndicate for the credit facility includes Citi and HSBC Bank Plc as joint coordinating book-runners. It also includes Barclays Capital, BNP Paribas, Credit Suisse, Goldman Sachs International, J.P. Morgan Plc., Morgan Stanley, Bank Hapoalim and Bank Leumi.
The Associated Press and Reuters contributed to this report
- Follow Ynetnews on Facebook
